About Biopharmx Corp (NYSE:BPMX)
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NYSE:BPMX
- CUSIP: N/A
- Web: www.biopharmx.com
- Market Cap: $23.1 million
- Outstanding Shares: 79,669,000
- 50 Day Moving Avg: $0.30
- 200 Day Moving Avg: $0.45
- 52 Week Range: $0.19 - $0.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.74
- P/E Growth: 0.00
- Annual Revenue: $83,999.00
- Price / Sales: 275.05
- Book Value: N/A
- Price / Book: N/A
- EBITDA: ($18,070,000.00)
- Net Margins: -22,005.88%
- Return on Equity: -5,749.08%
- Return on Assets: -240.31%
- Average Volume: 922,400 shs.
- Short Ratio: 4.6
Frequently Asked Questions for Biopharmx Corp (NYSE:BPMX)
What is Biopharmx Corp's stock symbol?
Biopharmx Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "BPMX."
How were Biopharmx Corp's earnings last quarter?
Biopharmx Corp (NYSE:BPMX) announced its quarterly earnings data on Tuesday, June, 14th. The company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.01. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%. View Biopharmx Corp's Earnings History.
When will Biopharmx Corp make its next earnings announcement?
Where is Biopharmx Corp's stock going? Where will Biopharmx Corp's stock price be in 2017?
1 equities research analysts have issued twelve-month price objectives for Biopharmx Corp's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Biopharmx Corp's share price to reach $3.00 in the next year. View Analyst Ratings for Biopharmx Corp.
Are investors shorting Biopharmx Corp?
Biopharmx Corp saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 4,147,107 shares, an increase of 2.1% from the September 15th total of 4,060,605 shares. Based on an average daily volume of 1,362,369 shares, the days-to-cover ratio is currently 3.0 days. Approximately 7.2% of the company's stock are sold short.
Who are some of Biopharmx Corp's key competitors?
Some companies that are related to Biopharmx Corp include Aldeyra Therapeutics (ALDX), Proteon Therapeutics (PRTO), ADMA Biologics (ADMA), Auris Medical Holding AG (EARS), Alcobra (ADHD), Zosano Pharma Corporation (ZSAN), Redx Pharma PLC (REDX), Celsion Corporation (CLSN), ANGLE plc (AGL), Imprimis Pharmaceuticals (IMMY), Orexigen Therapeutics (OREX), Egalet Corporation (EGLT), Aviragen Therapeutics (AVIR), Vical Incorporated (VICL), Pain Therapeutics (PTIE), Xenetic Biosciences (XBIO), Midatech Pharma PLC (MTPH) and Heat Biologics (HTBX).
Who are Biopharmx Corp's key executives?
Biopharmx Corp's management team includes the folowing people:
- James R. Pekarsky, Chairman of the Board, Chief Executive Officer
- Anja B. Krammer, President, Director
- Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
- Kin F. Chan Ph.D., Executive Vice President - Research & Development
- AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
- Stephen Morlock, Independent Director
- Charles Gregory Vontz, Independent Director
- Ping Wang, Independent Director
How do I buy Biopharmx Corp stock?
Shares of Biopharmx Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx Corp's stock price today?
MarketBeat Community Rating for Biopharmx Corp (NYSE BPMX)MarketBeat's community ratings are surveys of what our community members think about Biopharmx Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Biopharmx Corp stock can currently be purchased for approximately $0.29.
Earnings History for Biopharmx Corp (NYSE:BPMX)Earnings History by Quarter for Biopharmx Corp (NYSE BPMX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/12/2017|| || || || || || || || |
Earnings Estimates for Biopharmx Corp (NYSE:BPMX)
Current Year EPS Consensus Estimate: $-0.24 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS
Dividend History for Biopharmx Corp (NYSE:BPMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biopharmx Corp (NYSE:BPMX)Insider Trades by Quarter for Biopharmx Corp (NYSE:BPMX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/28/2016||Stephen Morlock||Director||Buy||428,571||$0.35||$149,999.85|| |
|8/15/2016||Franklin Resources Inc||Major Shareholder||Buy||484,615||$0.65||$314,999.75|| |
|3/29/2016||Franklin Resources Inc||Major Shareholder||Buy||540,000||$1.20||$648,000.00|| |
|1/14/2016||Stephen Morlock||Director||Buy||12,000||$1.52||$18,240.00|| |
|1/12/2016||Stephen Morlock||Director||Buy||6,000||$1.53||$9,180.00|| |
|1/7/2016||Stephen Morlock||Director||Buy||5,000||$1.47||$7,350.00|| |
|10/15/2015||Stephen Morlock||Director||Buy||5,000||$1.24||$6,200.00|| |
|10/9/2015||Stephen Morlock||Director||Buy||3,000||$1.21||$3,630.00|| |
Headline Trends for Biopharmx Corp (NYSE:BPMX)
Latest Headlines for Biopharmx Corp (NYSE:BPMX)
|BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017|
finance.yahoo.com - October 18 at 6:01 PM
|Biopharmx Corp (BPMX) Expected to Post Quarterly Sales of $20,000.00|
www.americanbankingnews.com - October 16 at 3:38 AM
|Biopharmx Corp (BPMX) Expected to Post Earnings of -$0.06 Per Share|
www.americanbankingnews.com - October 14 at 12:34 PM
|BioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery|
finance.yahoo.com - October 11 at 6:11 PM
|ETFs with exposure to BioPharmX Corp. : October 10, 2017|
finance.yahoo.com - October 10 at 5:57 PM
|Biopharmx Corp (BPMX) Short Interest Update|
www.americanbankingnews.com - October 10 at 5:20 PM
|Is BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock?|
finance.yahoo.com - October 2 at 1:52 PM
|$30,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter|
www.americanbankingnews.com - September 27 at 5:06 AM
|Short Interest in Biopharmx Corp (BPMX) Decreases By 5.7%|
www.americanbankingnews.com - September 27 at 1:18 AM
| Biopharmx Corp (BPMX) Receives Consensus Recommendation of "Strong Buy" from Brokerages|
www.americanbankingnews.com - September 19 at 2:38 AM
|BioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017|
finance.yahoo.com - September 14 at 5:23 PM
|BioPharmX Reports Second Quarter 2018 Financial Results - PR Newswire (press release)|
www.prnewswire.com - September 13 at 10:53 PM
|BioPharmX (BPMX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow|
seekingalpha.com - September 13 at 5:52 PM
|BioPharmX Reports Second Quarter 2018 Financial Results|
finance.yahoo.com - September 13 at 5:52 PM
|Biopharmx Corp (BPMX) Short Interest Down 2.9% in August|
www.americanbankingnews.com - September 13 at 1:26 AM
|BioPharmX (BPMX) Says Preliminary Data from Ongoing Rosacea ... - StreetInsider.com|
www.streetinsider.com - September 12 at 10:13 PM
|$20,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter|
www.americanbankingnews.com - September 9 at 5:32 PM
|BioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference|
finance.yahoo.com - September 5 at 6:17 PM
| Analysts Set $3.38 Price Target for Biopharmx Corp (BPMX)|
www.americanbankingnews.com - August 31 at 12:30 PM
| Biopharmx Corp (BPMX) Given Consensus Rating of "" by Analysts|
www.americanbankingnews.com - August 28 at 12:44 AM
| Brokerages Expect Biopharmx Corp (BPMX) Will Announce Quarterly Sales of $20,000.00|
www.americanbankingnews.com - August 21 at 5:08 AM
|Biopharmx Corp (NYSE:BPMX) Sees Significant Drop in Short Interest|
www.americanbankingnews.com - August 10 at 7:54 AM
| Brokerages Set $3.38 Price Target for Biopharmx Corp (NYSE:BPMX)|
www.americanbankingnews.com - August 8 at 7:44 AM
| Analysts Expect Biopharmx Corp (NYSE:BPMX) Will Announce Quarterly Sales of $20,000.00|
www.americanbankingnews.com - August 3 at 7:52 AM
| Brokerages Expect Biopharmx Corp (BPMX) Will Post Earnings of -$0.07 Per Share|
www.americanbankingnews.com - August 1 at 8:18 AM
|Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea - PR Newswire (press release)|
www.prnewswire.com - July 27 at 5:12 PM
| Biopharmx Corp (BPMX) Given Consensus Rating of "Strong Buy" by Brokerages|
www.americanbankingnews.com - July 24 at 9:14 AM
|Brokerages Expect Biopharmx Corp (BPMX) to Post ($0.07) EPS|
www.americanbankingnews.com - July 18 at 4:56 PM
|BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017 - PR Newswire (press release)|
www.prnewswire.com - July 13 at 10:49 PM
|BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017|
finance.yahoo.com - July 13 at 5:45 PM
|Biopharmx Corp (NYSE:BPMX) Short Interest Update|
www.americanbankingnews.com - July 13 at 7:00 AM
|ETFs with exposure to BioPharmX Corp. : July 12, 2017|
finance.yahoo.com - July 12 at 5:17 PM
|Exclusive: Biopharmx CFO Talks Trial Results, Competitive Prospects For BPMX Acne Treatment - Benzinga|
www.benzinga.com - May 8 at 3:54 PM
|BioPharmX (BPMX) Phase 2b Trail of BPX-01 Topical Minocycline for Acne Achieves Primary Endpoint; Secondary ... - StreetInsider.com|
www.streetinsider.com - May 3 at 9:06 PM
|BioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017 - StreetInsider.com|
www.streetinsider.com - April 20 at 4:08 PM
|BioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst - Benzinga|
www.benzinga.com - March 31 at 4:08 PM
|BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death|
us.rd.yahoo.com - March 30 at 4:24 PM
|BIOPHARMX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - March 29 at 4:21 PM
|BioPharmX Has A Major Upcoming Catalyst|
seekingalpha.com - March 27 at 3:58 PM
Biopharmx Corp (BPMX) Chart for Wednesday, October, 18, 2017